<DOC>
	<DOCNO>NCT02914353</DOCNO>
	<brief_summary>This First-In-Human study evaluate safety tolerability , pharmacokinetic profile , pharmacodynamic effect EP-7041 , novel Factor XIa inhibitor , follow IV administration single ascend dos healthy normal volunteer , follow continuous IV infusion multiple ascend dos healthy normal volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , PK PD Single Multiple Ascending Doses EP-7041 Healthy Subjects</brief_title>
	<detailed_description>This single-center , Phase 1a/1b , placebo-controlled , randomize , double-blind , integrated sequential ascend dose / multiple ascend dose study . The study divide two part : single ascend dose evaluation healthy normal volunteer constitute Part A multiple ascend dos evaluation healthy normal volunteer constitute Part B . The two study part perform sequentially partial overlap . Part A include 6 cohort ( 1 cohort per dose level ; 4 plan cohort 2 optional adaptive cohort ) . Each cohort include 8 subject - 6 active drug 2 placebo - result maximum number 48 subject study - 32 plan 16 optional . Subjects cohort receive single IV slow bolus ( 50 mL 5 minute ) administration study medication placebo . The dose EP-7041 sequentially escalate cohort cohort Part A . A stagger dose schedule use cohort Part A : 2 sentinel subject ( 1 active 1 placebo ) dose first remain 6 subject dosed next day ( 5 active 1 placebo ) . Part B include 4 cohort ( 1 cohort per dose level ; 3 plan cohort 1 optional adaptive cohort ) . As Part A , cohort Part B include 6 subject active drug 2 placebo , total 8 subject per cohort . Part B therefore involve , maximum , 32 subject , 24 plan subject 8 optional subject . Subjects cohort Part B receive total 5 sequential 24-hour IV infusion EP-7041 match placebo . Evaluation safety tolerability EP-7041 include adverse event ( i.e. , seriousness , severity , relationship EP-7041 ) , vital sign , ECG , clinical laboratory parameter , physical examination , local response injection , body weight . Pharmacokinetic analysis perform measurement EP-7041 plasma concentration , follow single multiple IV dos . Pharmacodynamic effect EP-7041 evaluate measurement aPTT PT subject multiple time throughout course study .</detailed_description>
	<criteria>Male female , nonsmoker ( use tobacco product within 3 month prior screen ) , ≥18 ≤60 year age , Body Mass Index ( BMI ) &gt; 18.5 &lt; 32.0 kg/m2 weight least 60 kg great 100 kg . Healthy define : 1 . No history abnormal bleeding episode , e.g . nosebleed , abnormally heavy period , extensive bleeding injury , surgery dental work . 2 . A normal short physical examination normal vital sign ( heart rate ( HR ) , blood pressure ( BP ) tympanic body temperature ) . 3 . Normal laboratory test ( hematology , biochemistry , urinalysis , coagulation test ( aPTT PT ) . 4. absence clinically significant illness surgery within 4 week prior dose . 5. absence clinically significant history neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease . Any clinically significant abnormality abnormal laboratory test result find medical screening , investigator 's discretion , warrant exclusion positive test hepatitis B , hepatitis C , HIV . Use drug know induce inhibit hepatic drug metabolism within 30 day prior drug administration . Positive pregnancy test screening checkin ( Day 1 ) . Clinically significant ECG abnormality vital sign abnormality ( systolic blood pressure low 90 160 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 40 100 bpm ) screen checkin ( Day 1 ) . Participation clinical trial involve administration investigational market drug within 30 day ( 90 day biologics ) , five ( 5 ) halflives , whichever longer , prior first dose concomitant participation investigational study involve drug administration . Hemoglobin hematocrit clinically significantly less low limit normal screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Factor X !</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>embolism thrombosis</keyword>
	<keyword>enzyme inhibitor</keyword>
	<keyword>hematologic agent</keyword>
</DOC>